Actelion Pharmaceuticals Ltd

Hoffmann-la Roche Inc.

Other

Idorsia Pharmaceuticals Ltd

Vanda Pharmaceuticals Inc.

Martine Clozel

Walter Fischli

Thomas Weller

Martin Bolli

Christoph Boss

Henri Ramuz

Hamed Aissaoui

Georges Hirth

Kaspar Burri

Werner Neidhart

Volker Breu

Jean-Marie Cassal

Ralf Koberstein

Bernd-Michael Loffler

Marcel Muller

Thierry Sifferlen

Claus Mueller

Boris Mathys

Michael Scherz

Luca Piali

Oliver Nayler

Daniel Bur

Christoph Binkert

David Lehmann

Markus Von Raumer

Jörg Velker

Ivan Schindelholz

Marc Bellet

Marc Iglarz

Laetitia Pouzol

Marcel M Uller

Jean-Paul Clozel

Michael W Cappi

Bernd M Loffler

Philipp Kohler

Bernd-Michael L Offler

Wolfgang Robert Osterrieder, Deceased

Urs Regenass

Joerg Velker

Judith Marfurt

J&ouml;rg Velker

Walter Actelion Pharmaceuticals Ltd Fischli

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.

Pharmaceutical combination comprising a selective S1Preceptor agonist

The present invention concerns the compound aprocitentan, {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, and its use as endothelin receptor antagonist, in combination with other active ingredients or therapeutic agents including an angiotenin receptor blocker, and/or a calcium channel blocker, and preferably a diuretic which is a thiazide-like diuretic, in the prophylaxis or treatment of certain endothelin related diseases. The invention further relates to pharmaceutical compositions comprising aprocitentan in combination with said other active ingredients or therapeutic agents. The invention further relates to such pharmaceutical compositions comprising novel crystalline forms of aprocitentan.

Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

Pharmaceutical combination comprising ponesimod

Pharmaceutical combination comprising a selective S1P1 receptor agonist

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. 

Therapeutic compositions containing macitentan

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. 

The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer. 

Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.

Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor

The invention relates to novel sulfamic acid amides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases

The invention relates to novel 1,2,3,4-tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to a mammal.

Substituted 1,2,3,4-tetrahydroisoquinoline derivatives

The invention relates to novel pyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.

Pyridine derivatives

Growing community of inventors

Binningen, Switzerland

Martine Clozel